Don't want these Ads? Why not sign up as a Trials Central Supporter.

neils on wheels

Members
  • Content count

    429
  • Joined

  • Last visited

  • Days Won

    2

1 Follower

About neils on wheels

  • Rank
    Advanced Member
  • Birthday

Contact Methods

  • Website URL
    http://
  • ICQ
    0

Previous Fields

  • Club
    Stratford upon Avon

Profile Information

  • Location
    Cotswolds
  • Gender
    Male

Recent Profile Visitors

6,329 profile views
  1. is this it? They've been not moving forward with this one for about four decades.
  2. This is an interesting point, I've generally been of the view that restricting youths to a 125 so they learn to get the most from a bike, rather than be dragged around by a 250, is a good idea if you're going to be riding big sections in the future and need to squeeze the maximum out a 300cc engine. However, I do wonder if what is good for the majority does hold back the elite riders. I think I'm right in saying that the five riders who have dominated world trials for the last decade were all riding 250+ bikes in the world championship class at around the age that today's youths are still restricted to a 125. Certainly a good result for Gelabert at Sheffield, well done to him. Let's hope he is another who can step up to challenge the established top five. Regarding the week in week out competition and practicing with the best in the world: I completely agree, success breeds success and we see it in all sports and indeed other walks of life.
  3. @faussy In 2017 Trial GP, Gelabert, Farre & Price finished 11th, 12th & 13th in that order, so are they really as far apart as you suggest? A compounding question and rather damning fact, is why only one rider in the last decade, of any nationality, (Jamie Busto) has been able to break into the worlds top five.
  4. Well good luck to them, but honestly do you expect them to announce their status as importer by sounding pessimistic about the viability of the company, uncertain about the owner's commitment to his importers and unsure about continuity of supply for bikes & spares? Why will they succeed where Steve Saunders & Haven have failed?
  5. There is a hint here in Malc Rathmell's press release when Sherco signed Jack Sheppard "Sherco and I have spoken long and hard about trials and we feel the time is now right to go back to basics, trials at grass roots. We want to concentrate on national championships, classic trials, nationals and centre/club events." I guess they'll have Gelabert in the WTC, Emma Bristow iin the Ladies WTC and that's it. As for Cabestany, I wonder if we'll see him in the WTC?
  6. @petorius I am in the UK and I have had to do the same (on an employer's policy) and have answered 'yes' to this question. My rationale is that disclosure is the best policy, otherwise you risk a claim being denied in the unfortunate event that you did suffer a trials related injury.
  7. Perhaps the conclusion to this little story & the answer to philmario's original question is that not everyone is riding Jotagas because we can't work out how to pronounce the damn thing!
  8. I am not trying to make anyone appear foolish and if I have caused offence, then I apologise. However in the interest of accuracy, whilst the letter ‘J’ may be named ‘jota’ in Spanish, this does not mean it is pronounced, or ‘said’ jota as was stated in the earlier post. Happy Christmas to all from pedant’s corner.
  9. So not “Jota-me” then....
  10. How do you pronounce Jamie Busto? Jesus? Jamon?
  11. Probably needed a fag.
  12. In my opinion it is mostly down to lack of confidence in the company and it's ability to supply both bikes and back up. If everyone did want to buy a Jotagas (or are they called JGas? I can't keep up) could they provide sufficient supply?
  13. No and neither will twinshocks
  14. I think Iwan Roberts rides in a similar style. Each to their own, they both seem to do well enough.
  15. I've watched the first two episodes and reckon a bit more about the trial, less about the relationship between Ross & James Burroughs would be welcome. Is this what will bring trials to an external audience?